156 lines
No EOL
32 KiB
XML
156 lines
No EOL
32 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547878" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547878/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Miglitol - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Miglitol" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2021/01/12" /><meta name="citation_pmid" content="31643214" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547878/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Miglitol" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2021/01/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547878/" /><meta name="description" content="Miglitol is an alpha glucosidase inhibitor which delays intestinal absorption of carbohydrates and is used as an adjunctive therapy in the management of type 2 diabetes. Miglitol has not been linked to instances of clinically apparent acute liver injury." /><meta name="og:title" content="Miglitol" /><meta name="og:type" content="book" /><meta name="og:description" content="Miglitol is an alpha glucosidase inhibitor which delays intestinal absorption of carbohydrates and is used as an adjunctive therapy in the management of type 2 diabetes. Miglitol has not been linked to instances of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547878/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Miglitol/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547878/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C31357D7E3E11000000000029001D.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547878_"><span class="title" itemprop="name">Miglitol</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 12, 2021</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Miglitol.OVERVIEW"><h2 id="_Miglitol_OVERVIEW_">OVERVIEW</h2><div id="Miglitol.Introduction"><h3>Introduction</h3><p>Miglitol is an alpha glucosidase inhibitor which delays intestinal absorption of carbohydrates and is used as an adjunctive therapy in the management of type 2 diabetes. Miglitol has not been linked to instances of clinically apparent acute liver injury.</p></div><div id="Miglitol.Background"><h3>Background</h3><p>Miglitol is an inhibitor of intestinal alpha glucosidase which results in a decrease or delay in intestinal absorption of starch, disaccharides and dextrin. Miglitol is a deoxynojirimycin derivative similar in structure to glucose that inhibits alpha glucosidase activity in the intestinal brush border, blocking the breakdown of starch and disaccharides to absorbable monosaccharides and leading to a delay in carbohydrate absorption and thus blunting of the postprandial rise in blood glucose. Miglitol was approved for use in the United States in 1996 and was the second α-glucosidase inhibitor (after acarbose) introduced into clinical practice. The current indications are for management of glycemic control in type 2 diabetes used with diet and exercise alone or in combination with other oral hypoglycemic agents or insulin. Miglitol is available generically and under the brand name Glyset in tablets of 25, 50 and 100 mg. The typical initial dose in adults is 25 mg with each meal (with the first bite) followed by a gradual increase to a maximum of 100 mg three times daily. Miglitol causes malabsorption and gastrointestinal side effects are most common and flatulence, diarrhea, abdominal boating and rash. Severe adverse events can include rash and pneumatosis cystoides intestinalis. Hypoglycemia may occur with combinations of miglitol with other oral hypoglycemic agents.</p></div><div id="Miglitol.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In several large clinical trials, serum aminotransferase elevations were no more common with miglitol than with placebo, and all elevations that occurred were asymptomatic and resolved rapidly with stopping therapy. Neither during these studies nor since approval and wide clinical use have reports of clinically apparent liver injury due to miglitol been published. Thus, liver injury from miglitol must be very rare if it occurs at all. There also have been no reports of patients who developed liver injury while on acarbose being switched to miglitol.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Miglitol.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The reason why miglitol rarely causes liver injury is not known. Unlike acarbose, miglitol is absorbed orally, but it is rapidly cleared by the kidneys and has minimal hepatic metabolism. While similar to acarbose (which does cause liver injury) in its mechanism of action, miglitol is a structurally distinct.</p><p>Drug Class: <a href="/books/n/livertox/Antidiabetic/">Antidiabetic Agents</a></p><p>Other Drugs in the Subclass <a href="/books/n/livertox/AlphaGlucosidaseInhi/">Alpha Glucosidase Inhibitors</a>: <a href="/books/n/livertox/Acarbose/">Acarbose</a></p></div></div><div id="Miglitol.PRODUCT_INFORMATION"><h2 id="_Miglitol_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
||
<b>REPRESENTATIVE TRADE NAMES</b>
|
||
</p><p>Miglitol – Generic, Glyset®</p><p>
|
||
<b>DRUG CLASS</b>
|
||
</p><p>Antidiabetic Agents</p><p>
|
||
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=miglitol" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
||
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Miglitol.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Miglitol_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Miglitol.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547878/table/Miglitol.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Miglitol.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Miglitol.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Miglitol.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Miglitol.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Miglitol.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Miglitol.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Miglitol</td><td headers="hd_h_Miglitol.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135010524" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">72432-03-2</a>
|
||
</td><td headers="hd_h_Miglitol.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C8-H17-N-O5</td><td headers="hd_h_Miglitol.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135010524" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135010524" alt="image 135010524 in the ncbi pubchem database" /></a>
|
||
</td></tr></tbody></table></div></div></div><div id="Miglitol.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Miglitol_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 12 January 2021</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Miglitol.REF.zimmerman.1999">Zimmerman HJ. Oral hypoglycemic agents and other diabetes therapy. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott,1999: pp. 575-9.<div><i>(Textbook of hepatotoxicity published in 1999 mentions that several instances of serum enzyme elevations and at least two cases of liver injury with jaundice have been linked to acarbose use; no mention of miglitol).</i></div></div></li><li><div class="bk_ref" id="Miglitol.REF.bhardwaj.2007">Bhardwaj SS, Chalasani NP. Antidiabetic drugs. Cardiovascular and antidiabetic medications. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 611-7.<div><i>(Review of hepatotoxicity published in 2007 mentions that acarbose has been associated with hepatocellular injury despite the fact that it is minimally absorbed, but that miglitol has not been implicated in causing liver injury).</i></div></div></li><li><div class="bk_ref" id="Miglitol.REF.powers.2018">Powers AC, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In, Brunton LL, Hillal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 863-86.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Miglitol.REF.segal.1997.687">Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. <span><span class="ref-journal">Diabetes Care. </span>1997;<span class="ref-vol">20</span>:687–91.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9135927" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9135927</span></a>]<div>
|
||
<i>(Controlled trial of miglitol vs glyburide vs placebo for 24 weeks in 201 patients with diabetes; 4 patients had elevations of liver enzymes at the end of the study [1 on miglitol, 1 glyburide and 2 placebo], but all 4 had some degree of elevation before treatment initiation).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF5">Miglitol for type 2 diabetes mellitus. <span><span class="ref-journal">Med Lett Drugs Ther. </span>1999;<span class="ref-vol">41</span>(1053):49–50.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10368700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10368700</span></a>]<div>
|
||
<i>(Brief review of role of miglitol in type 2 diabetes; "increased aminotransferase activity has not been reported with miglitol"; otherwise, the average cost, efficacy and tolerance of miglitol are similar to acarbose).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.sels.1999.149">Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. <span><span class="ref-journal">Expert Opin Pharmacother. </span>1999;<span class="ref-vol">1</span>:149–56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11249557" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11249557</span></a>]<div>
|
||
<i>(Review of the mechanism of action of miglitol and summary of results of clinical trials; no discussion of side effects).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.campbell.2000.1291">Campbell LK, Baker DE, Campbell RK. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. <span><span class="ref-journal">Ann Pharmacother. </span>2000;<span class="ref-vol">34</span>:1291–301.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11098345" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11098345</span></a>]<div>
|
||
<i>(Systematic review of miglitol therapy of diabetes; rates of serum enzyme elevations during therapy with miglitol were low and similar to placebo).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.scott.2000.521">Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. <span><span class="ref-journal">Drugs. </span>2000;<span class="ref-vol">59</span>:521–49.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10776834" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10776834</span></a>]<div>
|
||
<i>(Systematic review of literature on miglitol; side effects of flatulence [15-24%], diarrhea [7-13%], and abdominal pain [1-3%] were common, partially dose related, and similar to rates with acarbose; "Unlike acarbose, treatment with miglitol was not associated with elevated serum transaminase levels").</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.carlson.2000.315">Carlson RF. Miglitol and hepatotoxicity in type 2 diabetes mellitus. <span><span class="ref-journal">Am Fam Physician. </span>2000;<span class="ref-vol">62</span>(2):315–318.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10929699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10929699</span></a>]<div>
|
||
<i>(Letter in response to a review article on treatment of diabetes correcting the statement that miglitol causes liver injury similar to that described with acarbose; in studies for up to 12 months, ALT elevations above 3 times the ULN occurred in 3% of acarbose-, but only 1% of miglitol treated patients with diabetes).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.chiasson.2001.989">Chiasson JL, Naditch L., Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. <span><span class="ref-journal">Diabetes Care. </span>2001;<span class="ref-vol">24</span>:989–94.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11375358" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11375358</span></a>]<div>
|
||
<i>(Controlled trial of 8 weeks of miglitol vs placebo with or without metformin in 324 patients with diabetes; there were no differences in biochemical test results among the treatment groups and no liver related serious adverse event).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.chitturi.2002.169">Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. <span><span class="ref-journal">Semin Liver Dis. </span>2002;<span class="ref-vol">22</span>:169–83.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12016548" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12016548</span></a>]<div>
|
||
<i>(Overview of hepatotoxicity of antidiabetic medications mentions that acarbose has been incriminated in hepatotoxicity, generally arising within 2-8 months of starting therapy with an acute hepatitis-like clinical picture, but that miglitol has not).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.van_de_laar.2005.154">van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. <span><span class="ref-journal">Diabetes Care. </span>2005;<span class="ref-vol">28</span>:154–63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15616251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15616251</span></a>]<div>
|
||
<i>(Review of 41 studies, 30 of acarbose, 7 miglitol, 1 voglibose and 3 combined; discusses relative rates of side effects in comparison to placebo overall, but does not mention hepatic effects specifically).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
||
<i>(Among 300 cases of drug induced liver injury in the US collected from 2004 to 2008, none were attributed to miglitol or acarbose).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div>
|
||
<i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 [11%] were attributed to drug induced liver injury, of which 4 were due to troglitazone, but none were attributed to miglitol or other antidiabetic medications).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF15">Drugs for type 2 diabetes. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2011;<span class="ref-vol">9</span>(108):47–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21778966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21778966</span></a>]<div>
|
||
<i>(Concise review of the role of current antidiabetes medications in management of type 2 diabetes).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
||
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed antidiabetic agents including miglitol).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.hern_ndez.2014.231">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div>
|
||
<i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to an antidiabetic agent including miglitol).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div>
|
||
<i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, four were attributed to antidiabetic agents, including metformin, sitagliptin and glibenclamide, but none specifically to miglitol).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.yokoh.2015.182">Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. <span><span class="ref-journal">J Diabetes Investig. </span>2015;<span class="ref-vol">6</span>:182–91.</span> [<a href="/pmc/articles/PMC4364853/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4364853</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25802726" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25802726</span></a>]<div>
|
||
<i>(Among 119 Japanese adults with type 2 diabetes incompletely controlled on stable doses of oral agents who had the addition of sitagliptin or miglitol, reductions in HbA1c levels were less with miglitol while adverse events were more common [40% vs 10%] and mostly gastrointestinal; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.komatsu.2018.1092">Komatsu M, Tanaka N, Kimura T, Fujimori N, Sano K, Horiuchi A, Sugiura A, et al. Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients. <span><span class="ref-journal">Hepatol Res. </span>2018;<span class="ref-vol">48</span>:1092–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29935004" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29935004</span></a>]<div>
|
||
<i>(Among 17 adults with type 2 diabetes and nonalcoholic steatohepatitis treated with miglitol for 12 months, ALT and HbA1c levels and body weight decreased overall as did liver biopsy scores for steatosis and inflammation but not for fibrosis or ballooning; there were no serious adverse events and no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF.hedrington.2019.2229">Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2019;<span class="ref-vol">20</span>:2229–35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31593486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31593486</span></a>]<div>
|
||
<i>(Review of the role of alpha glucosidase inhibitors in the therapy of type 2 diabetes mentions that side effects are largely gastrointestinal [diarrhea, abdominal pain, flatulence] and are transient and mostly dose dependent; no mention of ALT elevations or hepatotoxicity).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Miglitol.REF22">Drugs for type 2 diabetes. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2019;<span class="ref-vol">61</span>(1584):169–78.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31770362" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31770362</span></a>]<div>
|
||
<i>(Concise review of the mechanisms of action, clinical efficacy, side effects and costs of currently available drugs for type 2 diabetes mentions that miglitol and acarbose must be taken with each meal and can lower HbA1c levels by 0.5-1.0%; side effects are not discussed).</i>
|
||
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547878</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643214" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643214</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Migalastat/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Miglustat/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK547878&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK547878/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |